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Type 2 diabetes (T2D) is characterized by insulin resistance and
pancreatic b-cell dysfunction, the latter possibly caused by a de-
fect in insulin signaling in b-cells. We hypothesized that insulin’s
effect to potentiate glucose-stimulated insulin secretion (GSIS)
would be diminished in insulin-resistant persons. To evaluate
the effect of insulin to modulate GSIS in insulin-resistant com-
pared with insulin-sensitive subjects, 10 participants with im-
paired glucose tolerance (IGT), 11 with T2D, and 8 healthy
control subjects were studied on two occasions. The insulin se-
cretory response was assessed by the administration of dextrose
for 80 min following a 4-h clamp with either saline infusion
(sham) or an isoglycemic-hyperinsulinemic clamp using B28-
Asp-insulin (which can be distinguished immunologically from
endogenous insulin) that raised insulin concentrations to high
physiologic concentrations. Pre-exposure to insulin augmented
GSIS in healthy persons. This effect was attenuated in insulin-
resistant cohorts, both those with IGT and those with T2D. Insulin
potentiates glucose-stimulated insulin secretion in insulin-resistant
subjects to a lesser degree than in normal subjects. This is consis-
tent with an effect of insulin to regulate b-cell function in humans
in vivo with therapeutic implications. Diabetes 61:301–309,
2012
T
ype 2 diabetes (T2D) is characterized both by
impaired insulin sensitivity and impaired insulin
secretion. Multiple lines of evidence support the
hypothesis that the pancreatic b-cell is an insulin-
responsive tissue, and that insulin itself contributes to the
regulation of insulin secretion. Insulin receptors and the
major insulin receptor substrates (IRS-1 through IRS-4) are
present and functional in rodent and human b-cells (1–7).
In b-cell–speciﬁc insulin receptor knockout (bIRKO) mice,
glucose-stimulated insulin secretion is defective, and ani-
mals develop progressive glucose intolerance and/or di-
abetes (8). In isolated human b-cells, insulin potentiates
glucose-stimulated insulin secretion (9) and de novo in-
sulin synthesis (2). In parallel, human pancreatic islets
from patients with T2D have reduced RNA expression of
multiple insulin signaling proteins including the insulin
receptor IRS-2 and the serine/threonine protein kinase
Akt2, which could impair insulin signal transduction and
contribute to a diminished physiologic effect of insulin in
patients with T2D (10).
Previous studies to evaluate whether insulin modulates
its own secretion in humans in vivo have yielded incon-
sistent ﬁndings. Older studies, primarily assessing C-peptide
levels, reported that administration of exogenous insulin
at euglycemia inhibited or had no affect on insulin release
(11–19). Using a novel paradigm with two immunologically
distinct insulins, we recently demonstrated that pre-exposure
to insulin potentiates glucose-stimulated insulin secretion
(GSIS) in healthy subjects (20). Likewise, Anderwald et al.
(21) reported insulin release during normoglycemia is
modulated by exogenous insulin infusion, and the effect
was lost in insulin-resistant persons. However, similar to
previous studies, they did not have a direct measure of in-
sulin secretion and calculated insulin secretion from plasma
C-peptide concentrations by deconvolution, and the effect
of glucose stimulation of insulin secretion at variable in-
sulin was not assessed. We hypothesized that the effect of
insulin to modulate the b-cell insulin response to glucose
is attenuated in insulin-resistant persons, thereby pro-
viding a potential molecular link between the dual defects
in insulin resistance and secretion manifest in T2D.
RESEARCH DESIGN AND METHODS
The Committee of Human Studies of the Joslin Diabetes Center approved the
study. Written informed consent was obtained from all participants. Subjects
included 10 subjects with impaired glucose tolerance (IGT) and 11 subjects
with T2D as determined by a 75-g oral glucose tolerance test according to
American Diabetes Association criteria (22). The T2D subjects were only in-
cluded if they were newly diagnosed based on an oral glucose tolerance test,
were on lifestyle therapy only, or were on one oral hypoglycemic medication
that could safely be washed out for a period of 1 month. Blood pressure– and
lipid-lowering therapies were permitted for insulin resistant cohorts with
stable dosing over 2 months. A third group of subjects included eight healthy
persons with no ﬁrst-degree relative with diabetes and on no prescription
medications other than oral contraceptives. These healthy subjects have been
previously reported (20).
Studydesign.Each participantunderwent twostudy visits during which either
a 4-h saline infusion (sham clamp) or an isoglycemic-hyperinsulinemic clamp
was performed, both of which were immediately followed by graded glucose
administration for 80 min (Fig. 1A) (20). Subjects were instructed to refrain
from vigorous exercise and consume .250 g of carbohydrate per day for 3
days prior to each visit and were studied after a 10- to 12-h overnight fast. An
intravenous catheter was inserted into each arm, one for infusions and the
other for blood sampling. The arm used for phlebotomy was placed into a box
heated to 60°C to ensure arterialization of venous blood (23,24). Subjects were
blinded as to whether the sham or insulin clamp was being performed. Po-
tassium chloride (KCl) was administered at 10 mEq/h to prevent hypokalemia
during both clamps.
Duringtheﬁrstvisit(shamclamp),normalsalinewasinfusedfor4handwas
designed as a time and volume control for the isoglycemic-hyperinsulinemic
clamp performed at the second visit. Saline was infused at the volume rate
hypothetically required to maintain euglycemia during a hyperinsulinemic
clamp during which insulin (14 pmol/L/kg per min [2.0 mU/kg/min]) would be
administered (20,25) in a person with similar insulin resistance. For insulin
resistant and healthy control subjects, this corresponded to the volume cal-
culated for glucose utilization of 5 and 10 mg/kg/min, respectively. Saline in-
fusion for 240 min was followed by intravenous infusion of 20% dextrose at the
rates of 8 and 10 mg/kg/min for 40 min each (graded glucose infusion) to
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ORIGINAL ARTICLEinduce GSIS. As no insulin was administered during this ﬁrst (sham) study,
GSIS was evaluated following pre-exposure to low, endogenous insulin
concentrations.
During the second visit approximately 4 weeks later, subjects underwent an
isoglycemic-hyperinsulinemic clamp for 4 h (26). Insulin was administered as
a two-stepped primed (56 pmol/kg/min followed by 28 pmol/kg/min, each for
5 min), continuous infusion (14 pmol/L/kg per min [2.0 mU/kg/min]). This was
anticipated to increase insulin concentrations to about 1,400 pmol/L (200 mU/ml).
B28-Asp-insulin (Novolog; Novo Nordisk, Bagsværd, Denmark) was used be-
cause it has relative receptor binding and in vitro potency similar to regular
human insulin (27) but can be distinguished from endogenous insulin immu-
nologically by a novel method our group has devised and previously reported
(20). Infusion of 20% dextrose at a variable rate was used to match the plasma
glucose concentrations to those observed for that individual during the saline/
sham condition (i.e., maintain isoglycemia). After 4 h, additional 20% dextrose
was infused at variable rates to match glycemia during the graded glucose
infusion portion of the ﬁrst visit and to stimulate endogenous insulin secretion.
During this portion of the clamp both the insulin and variable-rate dextrose
infusions were continued so that insulin concentration remained elevated while
glucose concentrations observed in the subject during the sham condition were
matched. This study evaluated GSIS at matched glycemia following pre-
exposure to relatively high insulin conditions (compared with the sham clamp).
Assays. Glycohemoglobin was assessed by high-performance liquid chroma-
tography (Tosho 2.2;Tosho Bioscience). Potassium, total cholesterol,HDL, and
triglycerides were measured in the clinical laboratory of the Joslin Diabetes
Center (Beckman Synchron CX9). Serum glucose was measured using the
glucose oxidase method (YSI 2300 STAT). Immunoassays were performed in
duplicate in Joslin’s Specialized Assay Core Facility (Joslin Diabetes and En-
docrinology Research Center [DERC]) using commercial assay kits for total
insulin, measuring both endogenous (secreted) and exogenous (administered)
insulin and C-peptide (radioimmunoassay [RIA]; Diagnostic Systems Labora-
tories), with endogenous serum insulin assayed using an ELISA that would not
detect the administered B28-Asp-insulin (DAKO Insulin ELISA; DakoCytoma-
tion). Additional assays included serum free fatty acid (FFA) (NEFA FFA
ELISA, Wako Chemicals), proinsulin (total proinsulin, Mercodia), cortisol
(Diasorin), and glucagon (Millipore).
Statisticalanalysis. Subjectcharacteristics and dataare presented asmean 6
SE. The primary study end point of the study was the difference in rate of
insulin secretion, measured by endogenous insulin, in response to glucose
following pre-exposure to low versus high insulin conditions. A linear re-
gression of change in insulin per time was constructed for each subject during
GSIS as the change in glycemic stimulus ﬁt linear model assumptions despite
the two steps of dextrose administration during clamps. The mean rate of
increase on the insulin and sham days were compared by paired Student t test.
ANOVA was used for multiple comparisons by group with Fisher exact test for
between group comparisons. Student paired t tests were used for point
comparisons within groups. Repeated-measures ANOVA was used for com-
parisons of multiple time points between sham and hyperinsulinemic clamps
days. Results were considered signiﬁcant with two-tailed P values ,0.05.
Analyses were done with StatView (SAS Institute).
RESULTS
The clinical and metabolic characteristics of participants
are shown in Table 1. As anticipated, the T2D cohort was
modestly older (P = 0.0003), had higher fasting glucose
(P , 0.0001), hemoglobin A1c (P = 0.002), and systolic
blood pressure (P = 0.04), but unexpectedly tended to
have lower fasting insulin concentrations and lower BMI
than IGT and were more insulin sensitive (glucose utili-
zation over the last 2 h of clamp T2D vs. IGT: 7.1 6 1.3 vs.
5.1 6 2.7 mg/kg/min, P , 0.04). Control subjects were
younger, leaner, normoglycemic, and insulin sensitive (glu-
cose utilization 10.3 6 0.6 mg/kg/min P , 0.001, compared
with both T2D and IGT) without dyslipidemia.
Effects of pre-exposure to exogenous insulin on GSIS
GSIS. GSIS was measured during the 80 min of graded
glucose infusion (240–3 2 0m i n )u s i n gaD A K OE L I S Aa s s a y
that recognizes endogenous insulin but does not recognize
exogenous B28-Asp-insulin (20). In the absence of exogenous
insulin, RIA and ELISA insulin measurements were strongly
correlated (R
2 =0 . 9 4 ,P , 0.0001) (Fig. 1B). Healthy (insulin
FIG. 1. A: Study protocol: participants underwent paired isoglycemic clamp studies under high insulin (B28-Asp-insulin, 2 mU/kg/min) and low
insulin (saline-sham) conditions. Glucose (20% dextrose) was administered during insulin clamp to maintain isoglycemia and saline during sham
clamp as a time and volume control. Potassium chloride (KCl) was administered during all clamps. At the start of the 4th h of the clamp, additional
glucose was administered to investigate glucose-stimulated insulin secretion. During the sham clamp, the rate was 8 and 10 mg/kg/min for 40 min
each step; on the hyperinsulinic day, dextrose administration rates were variable to match the glycemic challenge achieved during the sham clamp
conditions. B: Correlation between the two insulin assays, RIA and ELISA, are demonstrated using samples obtained during the sham clamp study.
For conversion to Scientiﬁc International units: insulin (mU/mL) 3 6.945 pmol/L.
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measured by the difference in rate of increase in endogenous
insulin after pre-exposure to high compared with low insulin
(saline/sham) clamp (P =0 . 0 4 )( F i g .2 A). The endogenous
insulin area under the curve corrected for baseline increased
about 40% (P = 0.07). The effect of insulin to potentiate GSIS
was diminished in both insulin-resistant cohorts (IGT and
T2D) (Fig. 2B and C). Whereas GSIS was increased in T2D
following pre-exposure to high insulin (P =0 . 0 1 ) ,t h e
magnitude of 22% was less than in control subjects. More
strikingly, GSIS was not increased at all after exogenous
insulin exposure in the IGT cohort (P = 0.14), which
manifested the greatest magnitude of insulin resistance.
Likewise there was no change in endogenous insulin area
under the curve in IGT.
Similarly, although glucose concentrations achieved
during the graded glucose infusion were higher in the IGT
and T2D cohorts compared with control subjects, the en-
dogenous insulin concentrations achieved tended to be
higher for glycemia following high compared with low
insulin pre-exposure in control subjects; this was assessed
by comparison of the slope of change in insulin to change
TABLE 1
Clinical and metabolic characteristics of study subjects
Healthy control
subjects IGT T2D P value (ANOVA)
Age (years) 24 6 24 0 6 4** 55 6 2**,## ,0.0001
Sex 3M/5F 3M/7F 5M/6F NS†
BMI (kg/m
2) 22.5 6 0.7 33.4 6 4.4* 27.4 6 1.3 0.06
Systolic blood pressure (mmHg) 113 6 3 115 6 6 130 6 4*,# 0.04
Diastolic blood pressure (mmHg) 75 6 37 5 6 38 1 6 3 0.3
HbA1c (%) 5.1 6 0.1 5.5 6 0.2 6.5 6 0.2**,## ,0.0001
Glucose fasting (mmol/L) 4.44 6 0.22 5.05 6 0.17 6.55 6 0.39**,## ,0.0001
Insulin fasting (pmol/L) 35.5 6 4.9 91.7 6 17.4** 60.4 6 12.5 0.02
C-peptide (nmol/L) 0.57 6 0.03 1.53 6 0.27** 1.23 6 0.20* 0.01
Cholesterol (mmol/L) 3.89 6 0.21 4.30 6 0.28 4.40 6 0.26 0.4
Triglycerides (mmol/L) 0.55 6 0.07 1.39 6 0.40* 1.13 6 0.19 0.2
HDL (mmol/L) 1.30 6 0.10 1.01 6 0.05* 1.22 6 0.16 0.2
LDL (mg/dL) 2.33 6 0.16 2.77 6 0.23 2.64 6 0.26 0.5
M120–240 min (mg/kg/min) 10.3 6 0.7 5.1 6 0.9** 7.1 6 0.4**,# 0.0001
Data are mean 6 SE. Demographic information is provided for the three groups studied including IGT, T2D, and healthy control subjects.
Conversions of Scientiﬁc International to conventional units: glucose (mmol/L) O 0.0555 for mg/dL; insulin (pmol/L) O 6.945 for mU/mL;
C-peptide (nmol/L) O 0.333 for ng/mL; cholesterol, HDL, and LDL (mmol/L) O 0.0259 for mg/dL; triglycerides (mmol/L) O 0.0113 for mg/
dL. *P , 0.05 vs. controls; **P , 0.009 vs. controls; #P , 0.05 vs. IGT; ##P , 0.009 vs. IGT; †Chi square.
FIG. 2. Pre-exposure to isoglycemic hyperinslinemia potentiates glucose-induced insulin secretion in the insulin-sensitive persons (A), but the
effect is attenuated in insulin-resistant cohorts with IGT (B) or T2D (C). *P < 0.05. Black circles, isoglycemic-hyperinsulinemic clamp; white
circles, sham clamp.
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change in insulin over change in glucose, sham vs. insulin,
P = 0.099) (Fig. 3). The association was linear in all par-
ticipants except one control subject in whom the best ﬁt
was logarithmic. We did not deem exclusion of this in-
dividual justiﬁable on clinical grounds for primary analy-
sis, but analysis of the insulin-to-glucose relationship
without this individual was statistically signiﬁcant (P =
0.02). The change in insulin-for-glycemia effect was lower
in magnitude in T2D than the control subjects but statis-
tically signiﬁcant (0.09 6 0.03 vs. 0.13 6 0.04, sham vs.
insulin, P = 0.04) and absent in the IGT group (Fig. 3).
C-peptide. Fasting C-peptide concentrations were higher
in IGT and T2D compared with control subjects (Table 1).
Previous studies demonstrate exogenous insulin reduces
C-peptide concentrations (17), an effect that may be at-
tributed in part to increased C-peptide clearance (20). We
also demonstrated C-peptide concentrations to be reduced
from baseline during the 240 min of the isoglycemic-
hyperinsulinemic clamp compared with the sham clamp
in all groups (Fig. 4A–C). In response to glucose stimula-
tion, C-peptide concentrations increased. To adjust for the
lower C-peptide concentrations at steady state following
high compared with low (saline/sham) clamp conditions,
we calculated the fold increase in C-peptide during the
glucose stimulation. Similar to estimates of b-cell function
from measures of endogenous insulin, the fold increase in
C-peptide during glucose stimulation was increased most
following pre-exposure to exogenous insulin in the insulin-
sensitive cohort, intermediate in T2D (intermediate insulin
resistant) cohort but not signiﬁcant in the IGT cohort with
the greatest magnitude of insulin resistance, which is con-
sistent with an attenuation of the effect of insulin on GSIS in
insulin-resistant states (Fig. 4D–F).
Glycemia. As expected, fasting glucose concentrations
and glycemia achieved during the sham and hyper-
insulinemic conditions were higher in the IGT and T2D
cohorts than in control subjects (Fig. 5A–C, arrows). Im-
portantly, however, during both the 240 min prior to and
during the 80 min of the graded glucose infusion, the glu-
cose concentrations achieved were similar during the sham
and insulin clamps within each group for all three cohorts
(Fig. 5A–C).
Total insulin. Fasting insulin concentrations (DAKO
ELISA) were higher in the IGT and T2D cohorts compared
with control subjects (Table 1) but similar within each
group on the 2 study days (P $ 0.7 for all comparisons).
Fasting insulins and insulin concentrations throughout
saline infusion, sham clamp without B28-Asp-insulin, did
not differ by ELISA or RIA, and agreement between the
two assays was very high (R
2=0.94, P , 0.0001) (Fig. 1B).
We have previously demonstrated that the DAKO insulin
ELISA does not detect B28-Asp-insulin (20), thus on the
isoglycemic-hyperinsulinemic clamp study, DAKO insulin
represents only endogenous insulin. In each cohort, endog-
enous insulin concentrations were similar at time 240 min
FIG. 3. Higher glucose concentrations were achieved in the insulin-resistant cohorts (IGT and T2D) compared with control subjects. b-cell glucose
sensitivity tended to be higher following high compared with low insulin pre-exposure in control subjects. The effect of insulin pre-exposure on
change in insulin for glycemia was lower in magnitude in T2D than in control subjects, but statically signiﬁcant and absent in the IGT group. For
conversion to Scientiﬁc International units: glucose (mg/dL) 3 0.0555 for mmol/L; insulin (mU/mL) 3 6.945 pmol/L. CON, control subjects. *P 5
0.04 vs. control.
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hyperinsulinemic clamps studies.
By design, total insulin levels (endogenous plus exoge-
nous) by RIA (60–240 min) remained low on the day of the
sham clamp (IGT: 76.4 6 2.1 pmol/L [11.0 6 0.3 mU/ml];
T2D: 48.6 6 3.5 pmol/L [7.0 6 0.5 mU/ml]; control subjects:
25.0 6 1.4 pmol/L [3.6 6 0.2 mU/ml]), but were markedly
increased during the hyperinsulinemic clamp with steady-
state concentrations in IGT, T2D, and control of 2,275 6 33;
1,528 6 23; and 1,095 6 16 pmol/L [327.7 6 4.8, 220.5 6 3.3,
and 157.6 6 2.3 mU/ml], providing a high physiologic level
of insulin pre-exposure before the glucose infusion
(hyperinsulinemic clamps vs. sham clamps, P , 0.0001 in all
cohorts) (Fig. 5D–F). Higher total insulin levels in the IGT
cohort compared with the T2D cohort likely resulted be-
cause insulin dosing was weight-based (14 pmol/kg/min [2.0
mU/kg/min]), and the IGT cohort was heaviest (Table 1).
Glucose utilization during GSIS. As expected, glucose
requirements to maintain similar glycemia during the
graded glucose infusion phase of the clamp were markedly
higher following pre-exposure to insulin. To main-
tain equivalent plasma glucose levels after insulin com-
pared with saline (sham) pre-exposure, an additional
83 6 6 mmol $ kg
21 $ min
21 (15 6 1m g$ kg
21 $ min
21)w e r e
infused in control subjects, 89 6 50 mmol $ kg
21 $ min
21
(16 6 9m g$ kg
21 $ min
21) in the IGT cohort, and 78 6 28
mmol $ kg
21 $ min
21 (14 6 5m g$ kg
21 $ min
21)i nT 2 D .
Other hormones and metabolites. Despite closely
matched glycemia between the two experimental con-
ditions, hyperinsulinemia can induce changes in other
hormones and metabolites, which could also participate in
the b-cell secretory response. Glucagon concentrations
were lower during the ﬁrst 240 min of hyperinsulinemic
clamps compared with sham clamps (P , 0.01) in all
cohorts, consistent with an effect of insulin on the a-cell
(28), and glucagon concentrations were further lowered
following endogenous insulin secretion during the GSIS
phase in IGT (Fig. 6A). Plasma FFAs were lower throughout
the hyperinsulinemic clamps compared with sham clamps
(Fig. 6B). While cortisol was higher in the control subjects
at euglycemic hyperinsulinemia (time 240 min), and lower
in the two insulin resistant cohorts following hyperglycemic
hyperinsulinemia (time 320 min), in general the effect of
diurnal variation was more pronounced than the differences
between clamp conditions (Fig. 6C). Although potassium
chloride was coadministered during all clamp protocols to
FIG. 4. A–C: Fasting C-peptide concentrations (time 0 min) were similar in control subjects, IGT, and T2D cohorts on both study days. C-peptide
concentrations were lower in all groups following isoglycemic hyperinsulinemia (time 240 min). D–F: The fold increase in C-peptide in response to
glucose stimulation was signiﬁcantly increased following pre-exposure to insulin in control subjects and T2D. The magnitude of effect was di-
minished in the insulin-resistant groups. *P < 0.05, **P < 0.01. Black circles, isoglycemic-hyperinsulinemic clamp; white circles, sham clamp. For
conversion to Scientiﬁc International units: C-peptide (ng/mL) 3 0.333 for nmol/L.
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concentrations were signiﬁcantly lower during the hyper-
insulinemic clamps compared with the sham clamps during
graded glucose infusions in all groups (Fig. 6D).
DISCUSSION
Insulin resistance and b-cell dysfunction are largely re-
garded as two distinct processes participating in the path-
ogenesis of T2D. Recent data demonstrate that insulin itself
augments GSIS in isolated human islets (2), rodent models
(8,29), and healthy humans in vivo (20), suggesting an im-
portant physiologic role of insulin to modulate b-cell func-
tion in humans in vivo. Here we demonstrate that insulin’s
affects to augment GSIS are diminished in insulin-resistant
persons with IGT and T2D. Thus, insulin resistance at the
level of the b-cell could represent a novel mechanism
coupling insulin resistance and b-cell dysfunction.
Our ﬁndings in humans are consistent with the multiple
genetic rodent studies demonstrating insulin’s positive
physiologic affects on b-cell mass and function. Mice with
bIRKO manifest diminished GSIS and progressive glucose
intolerance progressing to overt diabetes in some animals
(8,29). Likewise, deletion of insulin signaling proteins IRS-1,
IRS-2, phosphoinositide 3-kinase (PI3K), or the serine/
threonine protein kinase Akt2 alters glucose sensing and
b-cell growth (1,30–32). Insulin and the insulin-mimetic
compound L-783281 enhance insulin synthesis in isolated
rodent islets (33,34). Exogenous insulin also leads to in-
creased intracellular Ca
2+, suggesting insulin may promote
its own secretion by mobilizing Ca
2+ from the endoplasmic
reticulum (35). Higher insulin concentrations may induce
b-cell glucokinase expression, potentiating glucose-
stimulated insulin release. Moreover, glucose affects on b-cell
growth and survival require activation of insulin signaling
proteins (36), and hyperglycemia-induced reduction in expres-
sion of insulin receptor and activation of the proapoptotic
cascade is physiologically antagonized by insulin signaling
through the insulin signaling (IRS-PI3K-AKT-Bad) cascade
(37,38). However, while multiple studies demonstrate an
important role for the insulin signaling pathway in b-cell
development and function, the physiologic role of insulin
signaling on b-cell function has not previously been clearly
demonstrated in humans in vivo.
Recently, we developed a novel methodology for direct
measurement of endogenous insulin secretion in the pres-
ence of exogenous insulin by infusing an insulin analog
that is biologically equivalent to—but can be discriminated
FIG. 5. Glucose concentrations were similar following pre-exposure to saline (sham clamp) or insulin (isoglycemic-hyperinsulinemic clamp) for
control subjects (A), IGT (B), and T2D (C). Glucose levels achieved were greater in the IGT and T2D groups than in control subjects (→). Insulin
levels were higher following exogenous insulin administration (isoglycemic-hyperinsulinemic clamp) than saline (sham clamp) as demonstrated by
insulin RIA that detects both endogenous and exogenous insulin (D–F). The rise in total insulin can be seen in all cohorts following glucose
administration following pre-exposure to insulin or saline due to endogenous insulin. Insulin concentrations achieved during hyperinsulinemic
clamp were modestly higher in IGT and T2D cohorts compared with control subjects. Black circles, isoglycemic-hyperinsulinemic clamp; white
circles, sham clamp. For conversion to Scientiﬁc International units: glucose (mg/dL) 3 0.0555 for mmol/L; insulin (mU/mL) 3 6.945 pmol/L. CON,
control subjects; INS, insulin; GGl, graded glucose infusion.
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can use a selective immunoassay to accurately distinguish
endogenous insulin from the infused product (20). We have
previously reported an effect of insulin to augment GSIS in
healthy humans (20). To our knowledge, our dynamic
study is the ﬁrst to demonstrate that the effect of insulin
to augment secretion following glucose stimulation is di-
minished in insulin-resistant persons. Our data are consis-
tent with the recent ﬁndings of Anderwald et al. (21), which
demonstrated at euglycemia, in the absence of additional
glucose stimulation, insulin infusion leads to increased
insulin secretion in insulin-sensitive—but not insulin-
resistant—subjects. However, previous studies have not
yielded consistent ﬁndings. Our ﬁndings were most ap-
parent during the highest rate of glucose infusion, which
could be due to either glucose dose or duration of b-cell
exposure. Several factors could account for the largely
negative ﬁndings of older studies (11–16,18,19,39). First,
most prior studies were performed at euglycemia and
therefore did not evaluate the effect of glucose-stimulated
insulin secretion. Second, the presence or magnitude of
insulin resistance in subjects was not accounted for in
many prior studies, which may have inﬂuenced the results
given our ﬁndings that the effect is altered in insulin re-
sistance. Third, most studies relied on C-peptide measures
to estimate b-cell function as a substantial portion of en-
dogenously secreted insulin is sequestered and/or cleared by
insulin receptor–mediated mechanism(s) in the liver (40),
but C-peptide clearance measured using stable isotopic in-
fusion methods is increased during hyperinsulinemia (20),
and intracellular insulin processing may lead to altered in-
sulin to C-peptide secretion rates (41), which could bias
conclusions toward an underestimation of change in b-cell
response. Finally, most but not all prior studies (42) were
unable to distinguish exogenous from endogenous insulin
that may have masked the accurate interpretation of dy-
namic secretion.
We ﬁnd that both insulin-resistant cohorts have reduced
insulin potentiation of GSIS compared with healthy control
subjects, but it is worth distinguishing that the potentiation
effect was diminished in the T2D group and altogether
absent in the IGT cohort. This was unanticipated as the
FIG. 6. Hormone and metabolites during isoglycemic-hyperinsulinemic and sham clamps are shown for glucagon (A), FFAs (B), cortisol (C), and
potassium (D) at baseline (time = 0 min) and following insulin (black bars) or sham (gray bars) clamp, before (time 240 min) or after (time 320
min) glucose-induced insulin secretion. *P < 0.05. Black bars, isoglycemic-hyperinsulinemic clamp; gray bars, sham clamp. For conversion to
Scientiﬁc International units: glucagon (pg/mL) 3 1.0 for ng/L; FFA (mEq/L) 3 1.0 for mmol/L; cortisol (mg/dL) 3 27.59 for nmol/L; potassium
(mg/dL) 3 1.0 for mmol/L.
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been predicted to have the greatest effect reduction. The
IGT group was more insulin resistant and tended to be more
overweight than the T2D group. The T2D group also had
relatively mild disease as evidenced by treatment by life-
style without pharmacologic intervention. Consequently,
insulin augmentation of the b-cell response to glucose in
our study was in fact maximally attenuated in the most in-
sulin-resistant group (IGT). We speculate additional life-
style or other environmental factors could contribute to
between-group differences. Multiple physiologic and patho-
physiologic processes regulate b-cell function and mass. For
example, it is possible that insulin signaling pathways cross-
talk with incretin signaling, and additional studies will reveal
whether this cross-talk is differentially regulated in patients
with IGT versus those with T2D. It is also possible that T2D
could have reduced b-cell mass or greater magnitude insulin
resistance in peripheral tissues relative to that of the b-cell
and, thus, manifest more advanced disease (dysglycemia)
with lesser magnitude of b-cell insulin resistance. However,
we demonstrate in two independent insulin-resistant cohorts
that the effect of insulin to potentiate glucose-stimulated in-
sulin secretion is reduced.
Since the T2D group was more dysglycemic, our ﬁndings
further suggest that the attenuation of insulin potentiation of
glucose-stimulated insulin secretion is not due to early glu-
cose dysregulation. Furthermore, if the effect of insulin to
augment b-cell function was mediated indirectly by pro-
viding b-cell rest, one might have anticipated the effect to be
similar in the IGT and T2D cohorts, which was not seen.
Moreover, the IGT cohort demonstrated signiﬁcantly
higher insulin levels at each glucose concentration achieved
during the clamp, suggesting that this cohort had rela-
tively preserved b-cell function with retained capacity to
compensate for insulin resistance by augmenting insulin
secretion. In contrast, the T2D cohort exhibited more
profound b-cell dysfunction despite better peripheral in-
sulin sensitivity. We hypothesize that the increased insulin
concentrations manifest in the IGT cohort already pro-
vided a maximum stimulatory effect on the b-cell such that
no further augmentation could be demonstrated during a
hyperinsulinemic clamp. The preserved, though diminished,
effect observed in the T2D cohort may suggest that the ef-
fect of insulin to stimulate GSIS is decreased but not en-
tirely lost as b-cell dysfunction progresses, and there is loss
of glucose sensitivity.
Glucose could play an important role in modulating the
effect of insulin to potentiate b-cell function. Lower mag-
nitude of glycemic stimulation could result in reduced
b-cell responsiveness to insulin. However, this does not
appear to have been the case in this study as glucose con-
centrations achieved during graded glucose infusions were
highest in the insulin-resistant cohorts. In addition, glucotox-
icity could diminish the effects of insulin to potentiate GSIS.
As expected, our insulin-resistant cohorts had higher fasting
and clamp glucoses than healthy control subjects. However,
the IGT cohort had a greater reduction in insulin potenti-
ation of GSIS but lower glycemia compared with T2D, so
glucotoxicity does not accurately explain our study ﬁndings.
Multiple other metabolic factors could be signiﬁcant in
mediating a diminished effect of insulin on b-cell function.
We have studied the effect of FFAs, and insulin augmen-
tation of GSIS cannot be attributed to insulin suppression
of FFA in healthy persons (43). Glucagon is another potent
nonglucose secretagogue that promotes insulin secretion
independent of the effects on glucose (44) and could have
altered b-cell response. However, glucagon concentrations
were reduced during hyperinsulinemic clamps, suggesting
physiologic insulin action at the level of the a-cell (28,45).
Likewise, low serum potassium has been associated with
attenuated insulin secretion (46), but it is unlikely that the
small differences in serum potassium seen in our cohorts
explain the observed results because concentrations were
similarly modestly reduced in the control subjects. Based
on our ﬁndings, we cannot exclude the possibility that in-
sulin potentiation of GSIS could be secondary to short b-cell
rest with insulin administration during the period of iso-
glycemic-hyperinsulinemic pre-exposure rather than di-
rectly modulated by insulin signaling, and that the interval
of rest was insufﬁcient to promote potentiation of GSIS in
the insulin-resistant cohorts. Additional important factors
that were not assessed in our studies could also contribute
to b-cell dysfunction, including inﬂammation (47) and islet
amyloid deposition (48,49).
We recognize our human in vivo experiments are limited
because we cannot demonstrate dynamic changes in in-
sulin signaling in b-cells directly. The differences in weight
and degree of insulin resistance in the IGT versus T2D
cohorts are additional study limitations. Finally, the two
insulin-resistant cohorts were older than the healthy con-
trol subjects, and we cannot exclude confounding effects
of age on insulin dynamics. Further studies are warranted
to better understand how insulin modulates b-cell function
in insulin-sensitive and -resistant populations.
In conclusion, we have demonstrated that while the b-cell
is insulin responsive and pre-exposure to insulin enhances
glucose-stimulated insulin secretion in healthy humans, this
effect is reduced in states of insulin resistance. Thus, we
demonstrate physiologically that the b-cell is an insulin-
responsive tissue in humans in vivo. Our ﬁndings are con-
sistent with a growing body of literature that suggests that
pancreatic b-cell dysfunction could be caused by a defect in
insulin signaling within b-cells, and this b-cell insulin re-
sistance may lead to a loss of b-cell function and/or mass,
contributing to relative hypoinsulinemia in response to
glucose stimulation and subsequent hyperglycemia. Our
ﬁndings also suggest that therapies for type 2 diabetes,
particularly insulin-sensitizing agents, may exert their effect
at least in part by restoring b-cell insulin sensitivity, there-
fore enhancing the capacity of the b-cell to secrete insulin
as a response to glucose stimulation.
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